Related references
Note: Only part of the references are listed.Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study
Thi Tuyet Nhung Vo et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Class-sparing regimens for initial treatment of HIV-1 infection
Sharon A. Riddler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy
Angela C. Huttner et al.
AIDS (2007)
A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial
Rodger D. MacArthur et al.
LANCET (2006)
Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses
Roger Chou et al.
LANCET (2006)
Immunological recovery and antiretroviral therapy in HIV-1 infection
M Battegay et al.
LANCET INFECTIOUS DISEASES (2006)
Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/μL in HIV type 1-infected individuals receiving potent antiretroviral therapy
GR Kaufmann et al.
CLINICAL INFECTIOUS DISEASES (2005)
Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort
C Torti et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005)
B Gazzard
HIV MEDICINE (2005)
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection
RM Gulick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors:: indirect comparison of controlled trials
Y Yazdanpanah et al.
BMJ-BRITISH MEDICAL JOURNAL (2004)
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV
K Squires et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2004)
Treatment for adult HIV infection - 2004 recommendations of the International AIDS Society-USA panel
PG Yeni et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection
GK Robbins et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years - The Swiss HIV cohort study
GR Kaufmann et al.
ARCHIVES OF INTERNAL MEDICINE (2003)
Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy
PW Hunt et al.
AIDS (2003)
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients
R van Leeuwen et al.
AIDS (2003)
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy:: a collaborative analysis of prospective studies
M Egger et al.
LANCET (2002)
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection
S Walmsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy
GR Kaufmann et al.
AIDS (2002)
Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy - The Swiss HIV Cohort Study
AC Friedl et al.
AIDS (2001)
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study
G Greub et al.
LANCET (2000)
Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy
E Wood et al.
AIDS (2000)
Share Paper
